Skip to content
Azilect(rasagiline)
Azilect (rasagiline) is a small molecule pharmaceutical. Rasagiline was first approved as Azilect on 2005-02-21. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against amine oxidase [flavin-containing] B.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Azilect (generic drugs available since 2016-03-15)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rasagiline mesylate
Tradename
Company
Number
Date
Products
AZILECTTevaN-021641 RX2006-05-16
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
azilectNew Drug Application2020-06-23
rasagilineANDA2022-02-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
parkinson diseaseEFO_0002508D010300G20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Rasagiline Mesylate, Azilect, Teva
78159422027-08-27DS, DPU-219
75728342026-12-05DP
ATC Codes
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04B: Dopaminergic agents
— N04BD: Mao b inhibitors, dopaminergic anti-parkinson drugs
— N04BD02: Rasagiline
HCPCS
No data
Clinical
Clinical Trials
56 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20431716745
Retinal detachmentD012163EFO_0005773H33.2———1—1
ApathyD057565———1—1
DepressionD003863F33.9———1—1
SchizophreniaD012559EFO_0000692F20———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Progressive supranuclear palsyD013494EFO_0002512G23.1——1——1
Restless legs syndromeD012148EFO_0004270G25.81—11——1
Rem sleep behavior disorderD020187EFO_0007462G47.52—11——1
SynucleinopathiesD000080874—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21—3———3
Alzheimer diseaseD000544EFO_0000249F03—2———2
Multiple system atrophyD019578—1———1
DementiaD003704F03—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Serotonin syndromeD020230EFO_1001842————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRASAGILINE
INNrasagiline
Description
Rasagiline is an indane that consists of 1-aminoindane bearing an N-propargyl substituent. A selective, irreversible monoamine oxidase-B inhibitor. It has a role as an EC 1.4.3.4 (monoamine oxidase) inhibitor and a neuroprotective agent. It is a secondary amine, a member of indanes and a terminal acetylenic compound.
Classification
Small molecule
Drug classMonoamine oxidase (MAO) inhibitors, type B
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C#CCN[C@@H]1CCc2ccccc21
Identifiers
PDB5G6S
CAS-ID136236-51-6
RxCUI134748
ChEMBL IDCHEMBL887
ChEBI ID63620
PubChem CID3052776
DrugBankDB01367
UNII ID003N66TS6T (ChemIDplus, GSRS)
Target
Agency Approved
MAOB
MAOB
Organism
Homo sapiens
Gene name
MAOB
Gene synonyms
NCBI Gene ID
4129
Protein name
amine oxidase [flavin-containing] B
Protein synonyms
adrenalin oxidase, MAO, brain, MAO, platelet, MAO-B, Monoamine oxidase type B, tyramine oxidase
Uniprot ID
Q7Z6S2
Mouse ortholog
Maob (109731)
amine oxidase [flavin-containing] B (Q8C0B2)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,736 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
26,521 adverse events reported
View more details